The National Committee for Clinical Laboratory Standards reference broth macrodilution method for antifungal susceptibility testing was compared with the E test by testing 86 clinical isolates of Candida spp. and Cryptococcus neoformans. The MIC agreement rates for the two methods for Candida spp. were 73-89% within ± 1 doubling dilution and 87-100% within ±2 dilutions. For C. neoformans, agreement within ± 1 dilution was > 70% for all the agents tested except fluconazole for which agreement was 35%. Our data support the further evaluation of the E test as an alternative method for antifungal susceptibility testing. However, E test MICs of fluconazole for C. neoformans, particularly C. neoformans var. gattii should be interpreted with caution, as falsely elevated MICs may occur.
Introduction
Fungal infections are important causes of morbidity and mortality in immunocompromised patients (Anaissie, Bodey & Rinaldi, 1989; Beck-Sague et al., 1993) . The development of new antifungal agents, the rise in the incidence of infections caused by yeasts other than Candida albicans and reports of resistance to antifungal agents have increased the demand for in-vitro antifungal susceptibility testing (Smith et al., 1986; Anaissie et al., 1989; Wingard et al., 1991; Cameron et al., 1993; Rex et al., 1993) . However, such testing remains unstandardised. MICs of antifungal agents are influenced by many variables including medium composition and pH, incubation conditions, inoculum density and endpoint definition (Pfaller et al., 1990; Fromtlingef a/., 1993; Rex et al., 1993) . The National Committee for Clinical Laboratory Standards (NCCLS) has proposed a reference broth macrodilution method for susceptibility testing of yeasts (NCCLS, 1992) . However, the method is cumbersome and ill-defined endpoints with azole agents lead to difficulties in interpretation. A microdilution adaptation of the NCCLS M27-P proposed reference method (NCCLS, 1992) has recently been shown to be comparable to the latter for susceptibility testing of yeasts .
Simpler testing procedures are needed. The E test (AB Biodisk, Solna, Sweden) is an established method of susceptibility testing of bacteria. Recent studies suggest that it may be a convenient and reliable method of susceptibility testing of yeasts (Bolmstrom & Odds, 1994; Espinel-Ingroff, Bolstrom & Jones, 1994; Sewell, Pfaller & Barry, 1994;  Phone: +61(2)6336255; Fax: +61(2)8938659. 1994; Colombo et al., 1995) . However, in-vitro parameters have yet to be defined and experience with antifungal testing is limited.
We compared the use of the E test with the reference NCCLS broth macrodilution method in determining the susceptibilities of 86 clinical yeast isolates to five antifungal agents including fluconazole, ketoconazole and itraconazole.
Materials and methods

Yeast isolates
Eighty-six recent clinical yeast isolates from our laboratory's culture collection were tested. They comprised C. albicans (30 isolates), ten isolates each of Candida parapsilosis, Candida tropicalis, Torulopsis glabrata, Cryptococcus neoformans var. neoformans, C. neoformans var. gattii and six isolates of Candida krusei. Repeat isolates from the same patient were excluded. All isolates were recovered from clinical specimens, identified by standard methods (Warren & Shadomy, 1991) and stored as a suspension in water at ambient temperature until used. Before to testing, each isolate was passaged at least twice on Sabouraud's dextrose agar (Difco Laboratories, Detroit, Michigan) at 30°C for 24-48 h to ensure optimal growth characteristics.
Antifungal agents
Five antifungal agents obtained as reagent grade powders were tested: amphotericin B (Bristol-Myers Squibb, Noble Park, Victoria), 5-flucytosine (5FC; Roche Laboratories, Dee Why, NSW), fluconazole (Pfizer Australia Pty Ltd, Ryde, New South Wales),' ketoconazole (Janssen-Cilag, Lane Cove, NSW) and intraconazole (Janssen-Cilag, Lane Cove, NSW). Stock solutions were prepared using deionised water as a solvent for 5FC and 100% dimethyl sulphoxide for the other compounds. The initial stock concentrations were 2560 mg/L for all agents. Serial two-fold dilutions of each agent were prepared in RPMI-1640 medium (Gibco laboratories, Grand Island, NY) buffered to pH 7.0 with 0.165 M MOPS buffer (Sigma, St. Louis, USA). Final drug concentrations in each case ranged from 0.06 to 64 mg/L. E test strips were obtained from Australian Laboratory Services, Rockdale, N.S.W. and stored at -20°C until used.
MIC determinations
Broth macrodilution. This was performed according to NCCLS (1992) guidelines using the spectrophotometric method of inoculum preparation, a final inoculum concentration of 1-5 + 10 x 10 3 cells/ml, and RPMI-1640 medium buffered to pH 70 with MOPS. Yeast inocula (0-9 mL) were added to 12 x 75 mm polystyrene plastic tubes (Falcon 2054, Becton Dickenson, NSW) containing 0.1 mL of doubling dilutions of each antifungal drug. Drug-free and yeast-free control tubes were included in each run. The tubes were incubated in air at 35°C; MIC endpoints were determined according to the NCCLS recommendations at 48 h for Candida spp. and 72 h for C. neoformans (NCCLS, 1992) .
E test. This was performed according to the E test provisional technical guide available at the time of study (Anonymous, 1993) . Inoculum suspensions were prepared by homogenizing yeasts after culture for 24 h on Sabouraud's dextrose agar in 0-85% NaCl to achieve a 0-5 McFarland turbidity {Candida spp.). C. neoformans was cultured for 48-72 h and a 10 McFarland turbidity was obtained. In all cases, the inocula concentrations were adjusted to the appropriate turbidity with the aid of a spectrophotometer (530 nm wavelength).
RPMI-1640 agar with 2% glucose buffered with MOPS (pH 70) was used to test susceptibilities to amphotericin B and 5FC; potassium phosphate (pH 70) buffer was used in place of MOPS to prepare the E test plates for azole testing, as recommended by the manufacturers. Plates were then swabbed with the yeast suspension evenly in three directions. After allowing excess moisture to be absorbed by the agar, one E test strip was applied per plate. The plates were incubated at 35°C in air and read after 24 h for Candida spp. and after 48-72 h for C. neoformans. E tests were additionally performed using Casitone agar (Difco, Detroit USA), in accordance with a more recent recommendation by the manufacturers (Anonymous, 1994) , to determine the susceptibility of C. neoformans to fluconazole, after poor agreement with the reference method was noted using RPMI 1640 medium.
C. albicans ATCC 90028, C. albicans ATCC 90029, C. parapsilosis ATCC 90018, C. neoformans ATCC 90112 and C. neoformans ATCC 90113 were included as controls with each batch of organisms tested. For both test methods, MICs were recorded by two independent observers. E test MICs were rounded up to the next highest value to correspond with the standard two-fold dilution used in the reference broth method. To obtain reproducibility, the MIC determinations were repeated until at least two results were in agreement. E test MICs > 32 mg/L and < 0.002 mg/L were also included in the analysis. Discrepancies among MIC endpoints of no more than two doubling dilutions were used to calculate the percentage agreement.
Results
The susceptibilities of the yeast isolates to the five antifungal agents using RPMI 1640 medium are shown in Table I . In the E test, Candida spp. produced clearly detectable growth at 24 h in RPMI-1640 medium and MICs were determined at that time. Isolates of C. neoformans required 48-72 h incubation for detectable growth. A broad range of MIC values was obtained with all antifungal agents except for amphotericin B. The activities of each agent varied with the organism group tested.
Broth microdilution MICs demonstrated, as expected, that all six isolates of C. krusei were resistant to fluconazole with MICs ^64 mg/L. Most isolates of C. albicans and C. parapsilosis were susceptible, and C. glabrata and those of C. Iropicalis resistant to fluconazole. The MICs of fluconazole for two isolates of C. neoformans were 8 mg/L; these were obtained from patients infected with the human immunodeficiency virus (HIV) who had previously received fluconazole for the treatment of oral candidiasis. For C. rropicalis isolates, broth macrodilution MIC90 values for the azole agents were ^ 16-fold higher than for C. albicans and C. parapsilosis, and two to eightfold higher than for C. glabrata. The MICs of all the azoles tested for one isolate was >32 mg/L; this was associated with azole treatment failure.
Tables II and III summarise the percentage of MICs obtained by the E test that were within two dilutions of those obtained by the reference broth macrodilution method. The agreement between the two methods ranged from 73-89% within one dilution and 87-100% within two dilutions at 48 h for Candida spp., except C. tropicalis, for which the agreement was ^ 60% (± two dilutions; >40% ± one dilution). Agreement was best for C. glabrata (100% ± two dilutions and ^90% ± one dilution). For C. neoformans, agreement was >90% (±two dilutions) for all agents except fluconazole, for which •Numbers expressed as (log)i deviation from corresponding broth dilution MICs *C iropicalis strains. 'C. albicans (seven strains), C iropicalis (two strains). agreement was only 45%. These discrepancies were, generally, the result of lower MICs for C. tropicalis obtained by the E test; higher MICs for C. neoformans were noted for all the antifungal agents tested except ketoconazole, for which lower MICs were obtained using the E test.
Overall agreement was best (100% ± two dilutions, >85%+one dilution) for amphotericin B and 5FC. Of the azoles, fluconazole had the highest agreement followed by itraconazole and ketoconazole for Candida spp. The converse was observed in testing C. neoformans; 11 isolates of C. neoformans had E test MICs that were more than four-fold (two dilutions) higher than the broth dilution MICs. These comprised eight C. neoformans var. gatti and three C. neoformans var. neoformans. E test fluconazole MICs > 32 mg/L were noted; however the corresponding broth dilution MICs were < 1 0 mg/L. These isolates were obtained from patients who were successfully treated with fluconazole indicating that the broth dilution method more accurately predicted clinical response. Repeat suscepibility testing of C. neoformans isolates to fluconazole using Casitone agar resulted in an agreement of 65% (±two dilutions; 55% ± one dilution) between the two methods. However, E test MICs of > 32 mg/L in six C. neoformans var. gattii isolates was consistently observed; the corresponding broth dilution MICs ranged from 0.25-1.0 mg/L. Of the Candida spp., the lowest agreement (60% + two dilutions, 40% ± one dilution) for fluconazole was observed with C. tropicalis.
Problems encountered with MIC determination of the azoles included the presence of trailing endpoints in both methods (Figure) , especially for C. tropicalis. 'Light-bulb' phenomena and the presence of double zoning also occurred with the E test. In general, clearest end-points were seen with C. neoformans var. neoformans and the worst with C. tropical is.
Discussion
The present study supports the findings of previous comparisons between the E test and broth dilution techniques for antifungal susceptibility testing (Bolmstrom & Odds, 1994; Sewell et al., 1994; Colombo et al., 1995) . In general, there was a tendency to read E test MICs slightly lower; this may be due to the greater ease of visualising growth along a continuous gradient. The overall agreement (±two dilutions) between the E test and NCCLS reference method for azole susceptibility testing of Candida spp. was similar to that observed in two recent studies (Sewell et al., 1994; Colombo et al., 1995) . Sewell et al. (1994) noted that agreement, in fluconazole susceptibility testing, for C. glabrata and C. tropicalis was poorest (37% and 56%, respectively). In contrast, we found little disparity in MICs obtained by the two methods for C. glabrata. MIC disagreements among Candida spp. tested indicated that C. tropicalis represented the major problem.
Amphotericin B and 5FC gave the best agreement (± two dilutions) with the proposed NCCLS reference method in our study. In testing Candida spp., fluconazole was superior to itraconazole, which in turn outranked ketoconazole in percentage agreement achieved, as noted previously (Colombo et al., 1995) . However, fluconazole gave the poorest agreement in testing C. neoformans, especially for C. neoformans var. gattii with 55% of E test MICs being more than four-fold higher than broth dilution MICs using RPMI medium. This contrasts with the findings of other investigators (Espinel-Ingroff et al., 1994; Colombo et al., 1995) . Espinel-Ingroff et al. (1994) demonstrated that, agreement was highest for fluconazole (86-89%) and 5FC (90-94%) when tested against Candida spp. and C. neoformans. In their study, E test MICs were recorded using high resolution antifungal agar (HR Agar; Unipath, Basingstoke, England) as well as RPMI-1640 agar. HR medium is reported to support better growth of yeasts and thus may affect the clarity of azole endpoint determinations (Rex et al., 1993) . The use of Casitone agar in our study improved but did not eliminate the marked disparity observed with E test and broth dilution MICs for fluconazole in testing C. neoformans. The revised E test Technical Guide (Anonymous, 1994) presently recommends Casitone agar as the medium for azole susceptibility testing for yeasts. We noted trailing endpoints frequently using both the reference broth macrodilution and E test in testing azole susceptibility; however, this was not evident in testing C. neoformans isolates. This was especially problematic with C. tropicalis, as observed in a recent report by Colombo et al. (1995) . One of the more important variables in the determination of MICs for azoles is the inoculum density and every effort was made to ensure that this was standardised. Further investigations are therefore warranted in determining the optimal medium for clearer azole end-point determinations by different laboratories.
We read E test MICs for Candida spp. after 24 h of incubation as others have noted that agreement is poorer if endpoints are recorded after ^48 h incubation for fluconazole (Sewell et al., 1994) . For C. neoformans adequate growth for MIC determinations was evident at 48-72 h.
This study adds important information comparing the E test with the reference broth macrodilution method for antifungal susceptibility testing. Overall, the agreement within two dilutions was ^87%, with the exception of fluconazole in testing C. neoformans.
This occurred with the use of both RPMI 1640 and Casitone medium in performing the E test. The E test appears to be a convenient and reliable alternative method for susceptibility testing of yeasts. However, at present, our data suggest caution in interpreting E test MICs of fluconazole for C. neoformans, particularly C. neoformans var. gattii, as results may indicate false resistance.
